(吗啉-4-基)甲基三氟硼酸内盐 | 1268340-94-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: (吗啉-4-基)甲基三氟硼酸内盐
• 英文名称: (morpholin-4-yl)methyl-trifluoroborate internal salt
• 英文别名: (morpholinium-4-ylmethyl)trifluoroborate internal salt；trifluoro(morpholinomethyl)borate；N-(trifluoroboratomethyl)morpholine internal salt；trifluoro(morpholin-4-ium-4-ylmethyl)borate；Hydrogen trifluoro(morpholinomethyl)borate；hydron;trifluoro(morpholin-4-ylmethyl)boranuide
• CAS: 1268340-94-8
• 化学式: C₅H₁₀BF₃NO*H
• 分子量: 168.955
• InChiKey: FQKLIGKQQGNVHW-UHFFFAOYSA-O

物化性质

• 熔点：
  170-172℃

计算性质

• 辛醇/水分配系数(LogP)：
  -0.71
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  13.7
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 储存条件：
  室温且干燥环境下使用。

反应信息

• 作为反应物：
  描述：

  3-氯吡啶 、 (吗啉-4-基)甲基三氟硼酸内盐 在 palladium diacetate 、 caesium carbonate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 45.0h， 以64%的产率得到3-(4-morpholinylmethyl)-pyridine
  参考文献：
  名称：

  Reinvestigation of Aminomethyltrifluoroborates and Their Application in Suzuki−Miyaura Cross-Coupling Reactions

  摘要：

  A reinvestigation into the chemical composition of potassium aminomethyltrifluoroborates is reported. These trifluoroborato salts have been reassigned as zwitterionic ammoniomethyltrifluoroborates. Minor adjustments to the previously disclosed reaction conditions are reported that permit a similar level of activity as nucleophiles in Suzuki-Miyaura cross-coupling reactions.

  DOI：

  10.1021/jo2001066
• 作为产物：
  描述：

  吗啉 、 potassium (chloromethyl)trifluoroborate 以 四氢呋喃 、 叔丁醇 为溶剂， 反应 1.5h， 以87%的产率得到(吗啉-4-基)甲基三氟硼酸内盐
  参考文献：
  名称：

  Reinvestigation of Aminomethyltrifluoroborates and Their Application in Suzuki−Miyaura Cross-Coupling Reactions

  摘要：

  A reinvestigation into the chemical composition of potassium aminomethyltrifluoroborates is reported. These trifluoroborato salts have been reassigned as zwitterionic ammoniomethyltrifluoroborates. Minor adjustments to the previously disclosed reaction conditions are reported that permit a similar level of activity as nucleophiles in Suzuki-Miyaura cross-coupling reactions.

  DOI：

  10.1021/jo2001066

文献信息

• SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20210061802A1

  公开（公告）日：2021-03-04

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: R 1 , R 2 , R 4 , R 5 , and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  揭示了Formula (I)的化合物或其盐，其中：R1、R2、R4、R5和m在此处被定义。还揭示了使用这些化合物来抑制二酰甘油激酶α(DGKα)和二酰甘油激酶ζ(DGKζ)中的一个或两个活性的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面是有用的。
• FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
  申请人：SHANGHAI YINGLI PHARMACEUTICAL CO., LTD

  公开号：US20160214994A1

  公开（公告）日：2016-07-28

  Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.

  揭示了一种融合嘧啶化合物，其中间体，制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物，该化合物的药用可接受盐，水合物，溶剂合物，以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物，药用可接受盐，水合物，溶剂合物，以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂，可用于制备用于预防和/或治疗细胞增殖性疾病，如癌症，感染，炎症和自身免疫疾病的药物。
• [EN] 4,4-DISUBSTITUTED-1,4-DIHYDROPYRIMIDINES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] 1,4-DIHYDROPYRIMIDINES 4,4-DISUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE L'HÉPATITE B
  申请人：JANSSEN R & D IRELAND

  公开号：WO2013102655A1

  公开（公告）日：2013-07-11

  Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R1-R5, B and Z have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  公式（I）的HBV复制抑制剂包括立体化学同分异构体形式，以及其盐、水合物和溶剂合物，其中R1-R5、B和Z的含义如本文所定义。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HBV治疗中的使用，单独或与其他HBV抑制剂结合使用。
• WO2020021064A5
  申请人：——

  公开号：WO2020021064A5

  公开（公告）日：2022-08-03
• Cross-Coupling of Mesylated Phenol Derivatives with Potassium Ammonio- and Amidomethyltrifluoroborates
  作者：Gary A. Molander、Floriane Beaumard

  DOI：10.1021/ol200128y

  日期：2011.3.4

  A large array of aryl and heteroaryl mesylates have been successfully employed as electrophiles in a Csp(2)-Csp(3) Suzuki-Miyaura cross-coupling with potassium ammonio- and amidomethyltrifluoroborates to afford the corresponding products in high yields.